Management tracks: uniQure, Provention, Anaptys, FDA and more
uniQure N.V. (NASDAQ:QURE) promoted CSO Sander van Deventer to EVP, research and product development and Alex Kuta to EVP, operations from SVP, regulatory affairs. As a result, the gene therapy company said COO Scott McMillan will retire and the COO position will be eliminated. van Deventer is an operating partner at Forbion Partners and co-founded uniQure's predecessor Amsterdam Molecular Therapeutics. He will also continue to serve as general manager of UniQure's Amsterdam research and technology center of excellence.
Autoimmune and inflammatory disease company Provention Bio Inc. (NASDAQ:PRVB) hired Sherron Kell as SVP of clinical development. Kell was VP at Impax Laboratories Inc., which merged with Amneal Pharmaceuticals Inc. (NYSE:AMRX)...